Her2-low/ HRR proficient early triple negative breast cancer is characterized by good prognosis

被引：0

作者：

Pellegrino, B. ^{[1
]}

Tornali, C. ^{[2
]}

Lazzarin, A. ^{[3
]}

Cotelli, B. ^{[2
]}

Ingallinella, A. ^{[2
]}

Campanini, N. ^{[4
]}

Tommasi, C. ^{[5
]}

Coriano, M. ^{[6
]}

Serra, O. ^{[7
]}

Michiara, M. ^{[8
]}

Boggiani, D. ^{[9
]}

Schirone, A. ^{[10
]}

Casarini, C. ^{[11
]}

Cretella, E. ^{[12
]}

Zoppoli, G. ^{[13
,14
]}

Lambertini, M. ^{[15
]}

Botosso, M. ^{[16
]}

Cortesi, L. ^{[17
]}

Silini, E. M. ^{[18
]}

Musolino, A. ^{[19
]}

机构：

[1] Osped Maggiore Parma, Oncol Dept, Parma, Italy

[2] Univ Parma, Oncol, Parma, Italy

[3] Univ Parma, Med Oncol Dept, Parma, Italy

[4] Univ Parma, Fac Med & Chirurg, Pathol, Parma, Italy

[5] Univ Parma, Fac Med & Chirurg, Med Oncol & Breast Unit, Parma, Italy

[6] Azienda Osped Univ Parma, Oncol, Parma, Italy

[7] Univ Parma, Fac Med & Chirurg, Oncol, Parma, Italy

[8] Osped Maggiore Parma, Oncol, Parma, Italy

[9] Univ Hosp Parma, Oncol, Parma, Italy

[10] Arcispedale SantAnna AOU Ferrara, Med, Ferrara, Italy

[11] Nuovo Osped Sassuolo, Oncol, Sassuolo, Italy

[12] Osped Cent Bolzano ASDAA SABES, Oncol Dept, Bolzano, Italy

[13] Univ Genoa, Dept Internal Med, Genoa, GE, Italy

[14] Osped Policlin San Martino IRCCS, DiMI, Genoa, GE, Italy

[15] IRCCS AOU San Martino, IST Ist Nazl Ric Canc, Oncol, Genoa, Italy

[16] IOV Ist Oncol Veneto IRCCS, Oncol, Padua, Italy

[17] Azienda Osped Univ Policlin Modena, Haematol & Oncol Dept, Modena, Italy

[18] Univ Parma, Pathol, Parma, Italy

[19] Univ Parma, Fac Med & Chirurg, Dept Med, Parma, Italy

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.212

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

269P

引用

页码：S328 / S329

页数：2

共 50 条

[21] Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status
Raghavendra, A. S.
Zakon, D. B.
Jin, Q.
Strahan, A.
Grimm, M.
Hughes, M. E.
Cherian, M.
Vincuilla, J.
Parker, T.
Tarantino, P.
Mittendorf, E. A.
King, T. A.
Valero, V.
Tripathy, D.
Tolaney, S. M.
Tayob, N.
Lin, N. U.
Stover, D. G.
Barcenas, C. H.
Garrido-Castro, A. C.
ESMO OPEN, 2024, 9 (11)
[22] Exploring Real-World HER2-Low Data in Early-Stage Triple-Negative Breast Cancer: Insights and Implications
da Silva, Jesse Lopes
Carvalho, Giselle de Souza
de Albuquerque, Lucas Zanetti
Rodrigues, Fabiana Resende
Fernandes, Priscila Valverde
Kischinhevsky, Daniel
de Melo, Andreia Cristina
BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 337 - 347
[23] Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies
Bar, Yael
Fell, Geoffrey
Dedeoglu, Aylin
Moffett, Natalie
Vidula, Neelima
Spring, Laura
Wander, Seth A.
Bardia, Aditya
Ko, Naomi
Moy, Beverly
Ellisen, Leif W.
Isakoff, Steven J.
NPJ BREAST CANCER, 2025, 11 (01)
[24] Analysis of factors influencing the efficacy of NAC and prognosis between HER2-zero and HER2-low HR negative breast cancer
Liu, Jing-Jing
Zhang, Yi
Zhang, Shi-Chao
Liu, Xu
Wang, Shu-Nan
Liu, Xin-Yu
Zhang, Jin
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
[25] Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies
Bar, Yael
Dedeoglu, Aylin S.
Fell, Geoffrey G.
Moffett, Natalie J.
Boyraz, Baris
Ly, Amy
Bardia, Aditya
Moy, Beverly
Ellisen, Leif W.
Isakoff, Steven J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[26] Frequency and prognosis of HER2-low status in Mexican patients with metastatic breast cancer
Martinez-Cannon, Bertha Alejandra
Verduzco-Aguirre, Haydee Cristina
CANCER RESEARCH, 2023, 83 (05)
[27] Clinical outcomes of neoadjuvant chemotherapy in HER2-low early breast cancer
Gudelj, Dora
Cular, Katarina
Toula, Lea
Krizic, Marija
Popovic, Marina
Plavetic, Natalija Dedic
Kelecic, Ana
Ivanac, Gordana
Soce, Majana
Gjergjaj, Iva Kukal
Silovski, Tajana
CANCER RESEARCH, 2024, 84 (09)
[28] Prognostic and biologic significance of HER2-low expression in early breast cancer
Tarantino, P.
Jin, Q.
Tayob, N.
Jeselsohn, R.
Schnitt, S. J.
Vincuilla, J.
Parker, T.
Tyekucheva, S.
Lin, N. U.
Hughes, M.
Weiss, A. C.
King, T. A.
Mittendorf, E. A.
Curigliano, G.
Tolaney, S. M.
ANNALS OF ONCOLOGY, 2022, 33 : S124 - S124
[29] Clinicopathologic features of early stage HER2-low breast cancer.
Nashed, Rebecca
Barger, Hannah
Fishman, Brooke Taylor
Schlyer, Dylan A.
Makani, Neeharika Srivastava
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[30] Trastuzumab Deruxtecan in HER2-Low Breast Cancer
Schnog, John-John B.
Samson, Michael J.
Duits, Ashley J.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12): : 1143 - 1144

← 1 2 3 4 5 →